Biologics
Turbine, Daiichi Sankyo Expand Virtual Biology Collaboration to Accelerate ADC Discovery
Turbine, a leading virtual biology company, announced the expansion of its collaboration with Daiichi Sankyo following the successful completio...
September 24, 2026 | News
Thermo Fisher Launches CHO-K1 Media Panel to Boost Biologics Production
Thermo Fisher Scientific, the world leader in serving science, announced the Gibco™ CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed me...
September 24, 2026 | News
Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies
- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
September 24, 2026 | News
Tsingke Launches High-Throughput Validation Workflow for AI-Designed Proteins and Antibodies
Tsingke announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed pro...
September 24, 2026 | News
XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Th...
September 24, 2026 | News
Every First Approval in APAC, 2026: The Full List
Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...
September 23, 2026 | Analysis
WuXi XDC Achieves GMP Release for Singapore Bioconjugate Manufacturing Site
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...
September 23, 2026 | News
Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset
Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...
September 23, 2026 | News
Accro Bio Doses First Patient in Phase IIb Trial of RIPK2 Inhibitor AC-101 for Ulcerative Colitis
Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, an...
September 22, 2026 | News
Specialised Therapeutics, Incyte Expand Partnership to Bring Ruxolitinib Cream to Australia
Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: IN...
September 22, 2026 | News
Telix to Merge with ITM in $1.65B Deal, Building Global Radiopharmaceutical Powerhouse
Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities ac...
September 22, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
OGT Expands SureSeq NGS Indexing Capacity to 384 Samples per Run
OGT, a leading global provider of genomic research and diagnostic solutions, announced the expansion of its SureSeq™ Universal NGS Unique Dual Index ...
September 21, 2026 | News
Nona Biosciences Develops AI Language Model for Fully Human Heavy-Chain-Only Antibodies
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, annou...
September 18, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
